Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 850

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 850
---
 |     |                                 |           |
| Outstanding at December 31, 2024                 |     |                  | 6,403,818 |   |     | $                             |     5.11 |     |                                 | 7.44years |
| Exercisable at December 31, 2024                 |     |                  | 2,270,626 |   |     | $                             |     5.83 |     |                                 | 3.30years |

Options outstanding had an intrinsic value of $ 5,494,000and $ 1,964,000as of December 31, 2024 and December 31, 2023, respectively. As of December 31, 2024, there was $ 14,300,000of unrecognized stock compensation, which will be recognized over the next three years.

Restricted Stock units

Restricted stock units “RSU” were assumed from the merger issued to the former Chief Executive Officer and currently is a board of director for the Company and 57RSU will vest in June 2025 and June 2026. The table below summarizes activity related to RSUs.

|                                                                 |     | Number of RSU |     |
| Restricted stock units assumed from Kintara upon merger closing |     |               | 114 |
| Vesting of restricted stock units                               |     |               |   — |
| Balance as of December 31, 2024                                 |     |               | 114 |

The remaining RSUs assumed from the Kintara merger will vest on August 1, 2025 and August 1, 2026 and such shares are not accounted for until they vest.

<div align='center'>F-90</div>

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

Stock compensation expense

Total stock-based compensation expense was allocated as follows:

|                                        |     |   |      2024 |     |   |    2023 |
|:---------------------------------------|:----|:--|----------:|:----|:--|--------:|
| General and administrative             |     | $ |   843,111 |     | $ | 300,986 |
| Research and development               |     |   | 1,115,552 |     |   | 177,904 |
| Total stock-based compensation expense |     |